MCID: CNT005
MIFTS: 57

Central Nervous System Lymphoma

Categories: Rare diseases, Blood diseases, Neuronal diseases, Immune diseases, Cancer diseases

Aliases & Classifications for Central Nervous System Lymphoma

MalaCards integrated aliases for Central Nervous System Lymphoma:

Name: Central Nervous System Lymphoma 12 14
Primary Central Nervous System Lymphoma 69
Primary Cns Lymphoma 12
Cns Lymphoma 69
Microglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3234
ICD9CM 34 200.5
NCIt 46 C9301

Summaries for Central Nervous System Lymphoma

Disease Ontology : 12 A hematologic cancer that has material basis in lymphoma located in central nervous system.

MalaCards based summary : Central Nervous System Lymphoma, also known as primary central nervous system lymphoma, is related to primary central nervous system lymphoma and intraocular lymphoma. An important gene associated with Central Nervous System Lymphoma is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are NF-KappaB Family Pathway and Selenium Micronutrient Network. The drugs Methotrexate and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, brain and b cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Central Nervous System Lymphoma

Diseases in the Central Nervous System Lymphoma family:

Primary Central Nervous System Lymphoma

Diseases related to Central Nervous System Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 167)
# Related Disease Score Top Affiliating Genes
1 primary central nervous system lymphoma 33.9 BCL6 CDKN2A CXCL12 MGMT MYD88
2 intraocular lymphoma 32.5 BCL6 CXCL12 IL10
3 glioma 30.2 CDKN2A IL2 TP53
4 testicular lymphoma 30.0 BCL6 FOXP1 MYD88
5 acquired immunodeficiency syndrome 30.0 BCL6 IL10 IL2 TP53
6 leukemia, chronic lymphocytic 29.6 BCL6 CXCL12 IL2 TP53
7 lymphoma, non-hodgkin, familial 29.3 BCL6 CXCL12 IL2 MALT1
8 b-cell lymphomas 28.8 BCL6 CDKN2A FOXP1 MALT1 PRDM1 TP53
9 diffuse large b-cell lymphoma 28.8 BCL6 FOXP1 MALT1 MYD88 PRDM1 TP53
10 lymphoma 11.2
11 aids - neurological complications 11.0
12 primary cutaneous diffuse large b-cell lymphoma, leg type 10.5 CDKN2A MYD88
13 anaplastic oligodendroglioma 10.5 CDKN2A MGMT
14 colon lymphoma 10.4 BCL6 CDKN2A
15 retinitis pigmentosa 22 10.4 CDKN2A IL10
16 brain stem astrocytic neoplasm 10.4 CDKN2A TP53
17 immune suppression 10.4 IL10 IL2
18 spitz nevus 10.4 CDKN2A TP53
19 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
20 squamous cell carcinoma of the larynx 10.4 CDKN2A TP53
21 primary mediastinal large b-cell lymphoma 10.4 BCL6 FOXP1
22 bartholin's gland benign neoplasm 10.4 CDKN2A TP53
23 bladder carcinoma in situ 10.4 CDKN2A TP53
24 balanoposthitis 10.4 CDKN2A IL2
25 thyroid lymphoma 10.4 CDKN2A TP53
26 vulva squamous cell carcinoma 10.4 CDKN2A TP53
27 nasal cavity adenocarcinoma 10.3 CDKN2A TP53
28 bone squamous cell carcinoma 10.3 CDKN2A TP53
29 megaesophagus 10.3 CDKN2A TP53
30 scrotal carcinoma 10.3 CDKN2A TP53
31 plasmablastic lymphoma 10.3 BCL6 CDKN2A
32 glycogen-rich clear cell breast carcinoma 10.3 CDKN2A TP53
33 oral leukoplakia 10.3 CDKN2A TP53
34 clonorchiasis 10.3 IL10 IL2
35 anogenital venereal wart 10.3 CDKN2A TP53
36 nodal marginal zone b-cell lymphoma 10.3 BCL6 MALT1
37 balanitis xerotica obliterans 10.3 CDKN2A TP53
38 fibrillary astrocytoma 10.3 MGMT TP53
39 cervix uteri carcinoma in situ 10.2 CDKN2A TP53
40 human immunodeficiency virus infectious disease 10.2 CXCL12 IL10 IL2
41 retinitis pigmentosa 44 10.2 IL10 IL2
42 skin squamous cell carcinoma 10.2 IL10 MGMT TP53
43 chromosomal triplication 10.2 BCL6 MALT1
44 glioblastoma 10.2
45 anal squamous cell carcinoma 10.2 CDKN2A MGMT TP53
46 grade iii astrocytoma 10.2 CDKN2A MGMT TP53
47 immune deficiency disease 10.2 CXCL12 IL10 IL2
48 squamous cell carcinoma of the oropharynx 10.2 CDKN2A IL10 TP53
49 melanoma, cutaneous malignant 1 10.2 CDKN2A MGMT TP53
50 oligodendroglioma 10.2 CDKN2A MGMT TP53

Graphical network of the top 20 diseases related to Central Nervous System Lymphoma:



Diseases related to Central Nervous System Lymphoma

Symptoms & Phenotypes for Central Nervous System Lymphoma

GenomeRNAi Phenotypes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CDKN2A IL10 IL2 MALT1 MYD88 TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 CDKN2A IL10 IL2 MALT1 MYD88 TP53

MGI Mouse Phenotypes related to Central Nervous System Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.09 BCL6 CDKN2A CXCL12 IL10 IL2 MALT1
2 cardiovascular system MP:0005385 10.08 MYD88 PRDM1 TP53 BCL6 CDKN2A CXCL12
3 endocrine/exocrine gland MP:0005379 10.06 BCL6 CDKN2A IL10 IL2 MGMT MYD88
4 immune system MP:0005387 10.06 BCL6 CDKN2A CXCL12 IL10 IL2 MALT1
5 mortality/aging MP:0010768 10.06 BCL6 CDKN2A CXCL12 IL10 IL2 MALT1
6 liver/biliary system MP:0005370 9.91 BCL6 CDKN2A CXCL12 IL10 IL2 PRDM1
7 no phenotypic analysis MP:0003012 9.81 BCL6 CDKN2A CXCL12 IL10 IL2 MGMT
8 neoplasm MP:0002006 9.8 MGMT MYD88 PRDM1 TP53 CDKN2A IL10
9 reproductive system MP:0005389 9.56 BCL6 CDKN2A CXCL12 IL10 IL2 MYD88
10 respiratory system MP:0005388 9.17 BCL6 CDKN2A IL10 IL2 MGMT MYD88

Drugs & Therapeutics for Central Nervous System Lymphoma

Drugs for Central Nervous System Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 254)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
2
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 147-94-4 6253
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
4
Teniposide Approved Phase 4 29767-20-2 34698
5
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
6
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58-05-9 143 6006
7
Fotemustine Experimental, Investigational Phase 4
8 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
19 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
20 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
21 Folate Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
22 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
24
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
25
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
26
Ofloxacin Approved Phase 3 82419-36-1 4583
27
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
28
rituximab Approved Phase 2, Phase 3, Phase 1, Early Phase 1 174722-31-7 10201696
29
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
30
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
31
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
32 Thiotepa Approved, Investigational Phase 3,Phase 2 52-24-4 5453
33
Dalteparin Approved Phase 3 9005-49-6
34
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
36
Ondansetron Approved Phase 3 99614-02-5 4595
37
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
38
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
39
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
40
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
41
Morphine Approved, Investigational Phase 3 57-27-2 5288826
42
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
43
Levoleucovorin Approved, Investigational Phase 2, Phase 3, Phase 1 68538-85-2
44
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
45
Carmustine Approved, Investigational Phase 3,Phase 2 154-93-8 2578
46
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
47
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
48
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
49 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
50 Analgesics Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 161)

# Name Status NCT ID Phase Drugs
1 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
2 Treatment of Primary CNS Lymphoma Recruiting NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
5 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
6 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
9 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
10 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
11 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
12 Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL Recruiting NCT02836158 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
13 Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma Recruiting NCT02313389 Phase 3 Rituximab, Methotrexate, Temozolomide
14 High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma Recruiting NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
15 Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Enrolling by invitation NCT02657785 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
16 a Phase II Study in Primary Central Nervous System Lymphoma Unknown status NCT00455286 Phase 2 Methotrexate;Methylprednisolone;Temozolomide
17 Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma Unknown status NCT00003261 Phase 2 methotrexate;zidovudine
18 Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma Unknown status NCT00942747 Phase 2 temsirolimus
19 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
20 Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine Unknown status NCT00503594 Phase 2 Methotrexate and temozolomide;Methotrexate , procarbazine ,vincristine ,cytarabine
21 Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma (PCNSL) Unknown status NCT01985451 Phase 2 Pemetrexe;Temozolomide
22 Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma Unknown status NCT01735747 Phase 2 nedaplatin;vincristine;Temozolomide
23 Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma Unknown status NCT00989352 Phase 2 Methotrexate;Lomustine;Procarbazine;Rituximab
24 High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement Unknown status NCT00801216 Phase 2 High-dose sequential chemotherapy and autologous transplant
25 Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma Unknown status NCT00032149 Phase 1, Phase 2 cyclophosphamide;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
26 Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer Unknown status NCT00387530 Phase 2 oral sodium phenylbutyrate;valganciclovir
27 Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma Completed NCT00193973 Phase 2 Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
28 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Completed NCT01011920 Phase 2 Methotrexate;Ara-C;Rituximab;Thiotepa;BCNU
29 Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00006264 Phase 2 ganciclovir;zidovudine
30 Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Completed NCT02301364 Phase 2 Buparlisib (BKM120)
31 Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma Completed NCT00210314 Phase 2 high dose methotrexate;high dose cytarabine
32 Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074191 Phase 2 cytarabine;dexamethasone;lomustine;methotrexate;procarbazine hydrochloride
33 Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074178 Phase 2 cyclophosphamide;cytarabine;dexamethasone;etoposide phosphate;methotrexate
34 Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Completed NCT00068250 Phase 1, Phase 2 rituximab;methotrexate;temozolomide 100 mg/m^2;temozolomide 150 mg/m^2;temozolomide 200 mg/m^2;post-radiation therapy temozolomide
35 Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00000801 Phase 2 Filgrastim;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Cytarabine;Dexamethasone
36 High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study Completed NCT01083342 Phase 2 MTX, MVD, VIA
37 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma Completed NCT00003632 Phase 2 carmustine;cytarabine;etoposide;melphalan;methotrexate
38 Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS Completed NCT00002940 Phase 2 hydroxyurea
39 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma Completed NCT00003061 Phase 2 cytarabine;methotrexate
40 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00098774 Phase 2 cytarabine;etoposide;leucovorin calcium;methotrexate;temozolomide
41 Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00045539 Phase 2 leucovorin calcium;methotrexate;thiotepa
42 Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00727831 Phase 1, Phase 2 glucarpidase;leucovorin calcium;methotrexate
43 High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma Completed NCT01182415 Phase 2 High-dose chemotherapy
44 Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma Completed NCT00248534 Phase 2 methylprednisolone;temozolomide
45 Interferon Alfa in Treating Children With HIV-Related Cancer Completed NCT00002621 Phase 2
46 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
47 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
48 Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment Completed NCT00005811 Phase 2 topotecan hydrochloride
49 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)
50 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa

Search NIH Clinical Center for Central Nervous System Lymphoma

Genetic Tests for Central Nervous System Lymphoma

Anatomical Context for Central Nervous System Lymphoma

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Lymphoma:

18
Central Nervous System

MalaCards organs/tissues related to Central Nervous System Lymphoma:

38
Brain, B Cells, Liver, Bone, Breast, Bone Marrow, Kidney

Publications for Central Nervous System Lymphoma

Articles related to Central Nervous System Lymphoma:

(show top 50) (show all 697)
# Title Authors Year
1
Leakage correction improves prognosis prediction of dynamic susceptibility contrast perfusion MRI in primary central nervous system lymphoma. ( 29323247 )
2018
2
A case of primary central nervous system lymphoma arising at the site of remote herpes encephalitis. ( 29382621 )
2018
3
Identification of novel recurrent ETV6-IGH fusions in primary central nervous system lymphoma. ( 29432597 )
2018
4
Apparent diffusion coefficient value for a B-cell central nervous system lymphoma in a cat. ( 29383265 )
2018
5
Discrepancy Between Low Levels of mTOR Activity and High Levels of P-S6 in Primary Central Nervous System Lymphoma May Be Explained by PAS Domain-Containing Serine/Threonine-Protein Kinase-Mediated Phosphorylation. ( 29361117 )
2018
6
Spinal primary central nervous system lymphoma: Case report and literature review. ( 29429785 )
2018
7
Primary Central Nervous System Lymphoma-PART 1: Epidemiology, Diagnosis, Staging, and Prognosis. ( 29447417 )
2018
8
Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation. ( 29438500 )
2018
9
Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma. ( 29331383 )
2018
10
Presence of apoptosis distinguishes primary central nervous system lymphoma from glioblastoma during intraoperative consultation. ( 29336777 )
2018
11
Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). ( 29416652 )
2018
12
Intraoperative Flow Cytometry Enables the Differentiation of Primary Central Nervous System Lymphoma from Glioblastoma. ( 29330078 )
2018
13
Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing. ( 28084866 )
2017
14
Primary Central Nervous System Lymphoma With Light Chain Deposition Disease (Aggregoma). ( 29280764 )
2017
15
Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies? ( 28922238 )
2017
16
Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study. ( 28870957 )
2017
17
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse. ( 28012348 )
2017
18
Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. ( 28577579 )
2017
19
High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. ( 28581466 )
2017
20
Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. ( 28058506 )
2017
21
Primary central nervous system lymphoma in immunocompetent patients: A regional cancer center experience. ( 29404295 )
2017
22
Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding. ( 29299134 )
2017
23
Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma. ( 27959415 )
2017
24
Relapsed or refractory primary central nervous system lymphoma radiosurgery: Report of the International Gamma Knife Research Foundation. ( 29296450 )
2017
25
Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience. ( 29256330 )
2017
26
Radiotherapy as an alternative treatment option for primary central nervous system lymphoma patients who are noncandidates for chemotherapy. ( 29290994 )
2017
27
Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. ( 28805292 )
2017
28
Diagnosis and management of primary central nervous system lymphoma. ( 28950405 )
2017
29
Current management of primary central nervous system lymphoma. ( 28841800 )
2017
30
Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma. ( 28521029 )
2017
31
Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma. ( 28881844 )
2017
32
Advances in Pathobiology of Primary Central Nervous System Lymphoma. ( 28776551 )
2017
33
Comparison between Glioblastoma and Primary Central Nervous System Lymphoma Using MR Image-based Texture Analysis. ( 28638001 )
2017
34
Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. ( 28636991 )
2017
35
Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma. ( 28806317 )
2017
36
Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese. ( 29213063 )
2017
37
Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience. ( 28633037 )
2017
38
Effect of rituximab on primary central nervous system lymphoma: a meta-analysis. ( 28900847 )
2017
39
Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. ( 29333405 )
2017
40
Interim (18)F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. ( 28725988 )
2017
41
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( 27713090 )
2017
42
The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma. ( 28508176 )
2017
43
Monocyte chemoattractant protein 1 expression and proliferation in primary central nervous system lymphoma. ( 28693163 )
2017
44
Role of radiation therapy in primary central nervous system lymphoma : KROG 14-20 Collaborative Study of Brain and Lymphoma Committee. ( 28939931 )
2017
45
Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. ( 28982883 )
2017
46
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for pediatric primary central nervous system lymphoma in first complete remission. ( 28542721 )
2017
47
Advances in the management of primary central nervous system lymphoma. ( 28949937 )
2017
48
Clinicopathological Features and Outcomes in Primary Central Nervous System Lymphoma: A 10-year Experience. ( 29333016 )
2017
49
Hyperglycemia is associated with poor survival in primary central nervous system lymphoma patients. ( 28058711 )
2016
50
Neuroimaging in Central Nervous System Lymphoma. ( 27443998 )
2016

Variations for Central Nervous System Lymphoma

Cosmic variations for Central Nervous System Lymphoma:

9 (show all 34)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10656 TP53 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.742C>T p.R248W 5
2 COSM43448 TNFAIP3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2273C>G p.P758R 5
3 COSM5878666 TET2 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.4034A>C p.Y1345S 5
4 COSM4440710 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.70T>C p.S24P 5
5 COSM4440697 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1255T>A p.S419T 5
6 COSM4440708 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.458G>A p.G153E 5
7 COSM4440695 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1261G>C p.D421H 5
8 COSM4440707 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.596G>A p.S199N 5
9 COSM4440703 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1376G>A p.S459N 5
10 COSM4440696 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1256C>T p.S419F 5
11 COSM4440698 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1335G>T p.V445V 5
12 COSM4440709 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.148A>T p.I50F 5
13 COSM4440712 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.230C>T p.P77L 5
14 COSM4440706 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.637C>A p.H213N 5
15 COSM4440705 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1274G>T p.R425M 5
16 COSM4440713 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.229C>A p.P77T 5
17 COSM4440704 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1336T>G p.Y446D 5
18 COSM1716590 STAT5B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1924A>C p.N642H 5
19 COSM1155745 STAT3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1981G>C p.D661H 5
20 COSM97162 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.183G>A p.E62fs 5
21 COSM97163 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.556+1G>C p.? 5
22 COSM85940 MYD88 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.794T>C p.L265P 5
23 COSM517 KRAS haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.34G>A p.G12S 5
24 COSM306058 JAK3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1533G>T p.M511I 5
25 COSM5878665 DNMT3A haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2207G>T p.R736L 5
26 COSM1737939 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>G p.Y196D 5
27 COSM144393 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>A p.Y196N 5
28 COSM220734 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>C p.Y196H 5
29 COSM220736 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>G p.Y196C 5
30 COSM5045028 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.591G>C p.E197D 5
31 COSM220733 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>C p.Y196S 5
32 COSM43452 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>A p.F115I 5
33 COSM43451 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1010G>A p.R337Q 5
34 COSM43455 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>C p.F115L 5

Copy number variations for Central Nervous System Lymphoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 250739 9 21967751 21994490 Methylation deletion CDKN2A CNS lymphoma

Expression for Central Nervous System Lymphoma

Search GEO for disease gene expression data for Central Nervous System Lymphoma.

Pathways for Central Nervous System Lymphoma

Pathways related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.49 CXCL12 IL2 MALT1 MYD88
2
Show member pathways
11.89 IL2 MTR TCN2 TP53
3 11.81 BCL6 PRDM1 TP53
4 11.79 CDKN2A MGMT TP53
5 11.71 BCL6 CDKN2A TP53
6 11.69 BCL6 IL10 TP53
7 11.68 BCL6 CXCL12 IL10 IL2 MALT1 MYD88
8 11.65 CDKN2A MGMT TP53
9 11.61 CXCL12 IL10 IL2
10 11.56 CXCL12 MALT1 MYD88
11
Show member pathways
11.41 CDKN2A PRDM1 TP53
12 11.32 BCL6 IL10 PRDM1
13 11.06 BCL6 IL10 PRDM1
14 10.9 MTR TCN2
15 10.89 CDKN2A TP53
16
Show member pathways
10.88 CDKN2A TP53
17 10.84 CDKN2A IL2 TP53

GO Terms for Central Nervous System Lymphoma

Cellular components related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.62 BCL6 TP53

Biological processes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.88 BCL6 CDKN2A IL10 TP53
2 positive regulation of gene expression GO:0010628 9.86 CDKN2A MYD88 PRDM1 TP53
3 negative regulation of cell growth GO:0030308 9.71 BCL6 CDKN2A TP53
4 response to ethanol GO:0045471 9.7 IL2 MGMT TP53
5 cobalamin metabolic process GO:0009235 9.57 MTR TCN2
6 negative regulation of cell-matrix adhesion GO:0001953 9.55 BCL6 CDKN2A
7 regulation of inflammatory response GO:0050727 9.54 BCL6 FOXP1 MYD88
8 negative regulation of growth of symbiont in host GO:0044130 9.51 IL10 MYD88
9 positive regulation of interleukin-17 production GO:0032740 9.49 IL2 MYD88
10 response to molecule of bacterial origin GO:0002237 9.48 IL10 MALT1
11 replicative senescence GO:0090399 9.46 CDKN2A TP53
12 positive regulation of histone deacetylation GO:0031065 9.43 BCL6 TP53
13 positive regulation of regulatory T cell differentiation GO:0045591 9.4 BCL6 IL2
14 negative regulation of B cell proliferation GO:0030889 9.33 CDKN2A IL10 PRDM1
15 regulation of tumor necrosis factor production GO:0032680 9.32 FOXP1 MYD88
16 type 2 immune response GO:0042092 9.26 BCL6 IL10
17 negative regulation of apoptotic process GO:0043066 9.17 BCL6 IL10 IL2 MALT1 MGMT MYD88
18 negative regulation of B cell apoptotic process GO:0002903 9.13 BCL6 FOXP1 IL2

Molecular functions related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cobalamin binding GO:0031419 9.16 MTR TCN2
2 kinase activator activity GO:0019209 8.96 IL2 MALT1
3 protein self-association GO:0043621 8.92 FOXP1 MALT1 MYD88 TP53

Sources for Central Nervous System Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....